Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council
Medical Research Futures Fund (Commonwealth government) Office of Health and Medical Research
Omico
- License Information
-
More Information
Article History
Received: 24 July 2022
Accepted: 21 December 2022
First Online: 4 January 2023
Competing interests
: DMT is the CEO of Omico, a non-profit precision oncology program. He has received research support as well as honoraria and speakers bureau from Astra Zeneca, Roche, Pfizer, Novartis, Eisai, Beigene, Seattle Genetics, Janssen, Bayer, Microba, InterVenn, Merck. VT is deputy CEO of Omico. The remaining authors declare no competing interests.
